Englander Institute for Precision Medicine

Publications

Found 851 results
Author Title Type [ Year(Asc)]
2025
Nuzzo PVitale, Rodrigues S, Ribeiro CFidalgo, Teixeira IFerrari, Fanelli GNicolo', Bleve S, Ravera F, Pakula H, Pederzoli F, Nanus DM et al..  2025.  Targeting Cancer Metabolism: Therapeutic Potential of the Fatty Acid Synthase (FASN) inhibitors.. Crit Rev Oncol Hematol. :104910.
Yost KE, Zhao Y, Hung KL, Zhu K, Xu D, M Corces R, Shams S, Louie BH, Sarmashghi S, Sundaram L et al..  2025.  Three-dimensional genome landscape of primary human cancers.. Nat Genet. 57(5):1189-1200.
Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S et al..  2025.  Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.. Mol Cell.
Sternberg CN, Morgans AK.  2025.  Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway.. Future Oncol. 21(25):3227-3235.
Honigsberg R, Cruz T, Yoffe L, Tang MStephanie, Dicle O, Markowitz G, Michael M, Singh A, Altorki NK, Elemento O et al..  2025.  Tumor-specific draining lymph node CD8 T cells orchestrate an anti-tumor response to neoadjuvant PD-1 immune checkpoint blockade.. bioRxiv.
Nath S, Claridge S, Granados GLara, Assaad MAl, Park E, Cavallo J-A, Nuwere U, Ackon MEsi, De Boni L, Baker S et al..  2025.  Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer.. Cell Rep Med. 6(7):102218.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Unusual Presentation of Advanced Urothelial Cancer in a Young Patient.. Anticancer Res. 45(2):613-618.
Bonacci RE, McGill M, Le NThuy Anh, Barkarar M, Finnegan C, Wilson M, Ajagbe O, Udekwu CC, Gorski K, Manohar J et al..  2025.  Upregulation of the interferon-inducible antiviral gene RSAD2 in neuroendocrine prostate cancer via PVT1 exon 9 dependent and independent pathways.. J Biol Chem. :108370.
Elemento O, Khozin S, Sternberg CN.  2025.  The use of artificial intelligence for cancer therapeutic decision-making.. NEJM AI. 2(5)
2024
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H et al..  2024.  ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.. Elife. 13
Lira MCecilia, Vanpouille-Box C, Galluzzi L.  2024.  Adaptive inhibition of CGAS signaling by TREX1.. Trends Cancer. 10(3):177-179.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Animal models of disease: Achievements and challenges.. Methods Cell Biol. 188:xv-xxi.
Stenzl A, Armstrong AJ, Sboner A, Ghith J, Serfass L, Bland CS, Schijvenaars BJA, Sternberg CN.  2024.  Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology.. Eur Urol Focus.
Desai P, Zhou Y, Grenet J, Handelman SK, Crispino CM, Tarbay LN, Whitsel EA, Roboz G, Barac A, Honigberg M et al..  2024.  Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.. Cancer.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Author Correction: Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Rajendran S, Brendel M, Barnes J, Zhan Q, Malmsten JE, Zisimopoulos P, Sigaras A, Ofori-Atta K, Meseguer M, Miller KA et al..  2024.  Automatic ploidy prediction and quality assessment of human blastocysts using time-lapse imaging.. Nat Commun. 15(1):7756.
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
Shah Y, Kulm S, Nauseef JT, Chen Z, Elemento O, Kensler KH, Sharaf RN.  2024.  Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.. PLoS Comput Biol. 20(4):e1011990.
Meleshko D, Yang R, Maharjan S, Danko DC, Korobeynikov A, Hajirasouliha I.  2024.  Blackbird: structural variant detection using synthetic and low-coverage long-reads.. bioRxiv.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Chen X, Augello MA, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J et al..  2024.  Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.. Nat Commun. 15(1):10675.
Kepp O, Galluzzi L, Petroni G.  2024.  Cellular senescence and aging at the crossroad between immunity and cancer.. Methods Cell Biol. 181:xvii-xxiv.
Gao VR, Yang R, Das A, Luo R, Luo H, McNally DR, Karagiannidis I, Rivas MA, Wang Z-M, Barisic D et al..  2024.  ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.. Nat Commun. 15(1):9432.
Vitale I, Galassi C, Galluzzi L.  2024.  Chromosomal instability drives immunosuppression and metastatic dissemination.. Cell Res. 34(1):7-8.